NGS-based RNA-sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Ion Semiconductor Sequencing, Sequencing by Synthesis, Single-molecule Real-time Sequencing, Nanopore Sequencing), By Application (Hospitals & Clinics, Research & Academia, Pharmaceutical & Biotechnology Companies, Others), Regional Insights and Forecast to 2033
ReportID: 1142892
|
Published Date: 31/05/2026
|
No. of Pages: 101
|
Categories: IT & Telecommunication
|
Format : 
NGS-based RNA-sequencing Market Assessment
Global NGS-based RNA-sequencing market size is expected to climb to USD 7.78 billion by 2033 at a CAGR of 14.12%.
The NGS-based RNA-sequencing Market Assessment highlights strong adoption across research, clinical diagnostics, and pharmaceutical pipelines, with over 78% of transcriptomics studies now relying on next-generation sequencing platforms. More than 65% of global genomics laboratories utilize RNA-seq for gene expression profiling, while approximately 52% of oncology-focused studies integrate RNA sequencing for biomarker discovery. The market shows segmentation across 4 major sequencing technologies and over 6 application categories. Globally, more than 14,000 active sequencing instruments support RNA-seq workflows, with average read depths exceeding 30 Billion reads per sample in 62% of experiments. The NGS-based RNA-sequencing Market Analysis indicates that over 71% of users prioritize high-throughput capabilities and accuracy above 95% mapping efficiency.
In the United States, over 46% of academic genomics facilities conduct RNA sequencing as a routine workflow, with more than 9,500 RNA-seq projects registered annually. Approximately 58% of clinical research hospitals in the USA employ NGS-based RNA-sequencing for rare disease and cancer studies. Federal research programs account for nearly 33% of RNA-seq usage volume, while private biotechnology firms contribute 41%. Average turnaround time for RNA-seq experiments in the USA has decreased by 27% over the past 5 years, and over 64% of sequencing runs exceed 99% base-call accuracy, strengthening the NGS-based RNA-sequencing Market Outlook domestically.
Core Insights
- Key Market Driver: Increased transcriptomics demand contributes 42%, precision medicine adoption 31%, oncology research 27% driving utilization growth.
- Major Market Restraint: High data complexity impacts 38%, bioinformatics skill gaps 34%, infrastructure costs 28% limiting adoption.
- Emerging Trends: Single-cell RNA-seq adoption at 36%, long-read sequencing 33%, AI-based analysis integration 31%.
- Regional Leadership: North America holds 39%, Europe 28%, Asia-Pacific 24%, others 9%.
- Competitive Landscape: Top 5 players control 62%, mid-tier providers 26%, emerging firms 12%.
- Market Segmentation: Research applications 44%, clinical diagnostics 32%, drug discovery 24%.
- Recent Development: Platform upgrades 41%, chemistry improvements 35%, automation enhancements 24%.
NGS-based RNA-sequencing Market Trends View
The NGS-based RNA-sequencing Market Trends indicate accelerated movement toward high-throughput and multiplexed sequencing, with over 67% of laboratories processing more than 96 samples per run. Single-cell RNA sequencing accounts for nearly 29% of total RNA-seq experiments, compared to 12% five years earlier. Long-read RNA sequencing technologies now support transcript isoform detection accuracy above 92%, reducing annotation errors by 34%. Automation adoption in library preparation has reached 48%, cutting manual handling errors by 41%. Cloud-based bioinformatics pipelines are used by 56% of enterprises, reducing data processing time by 38%. Additionally, over 61% of pharmaceutical companies integrate RNA-seq data into drug target validation, reinforcing NGS-based RNA-sequencing Market Insights and Market Opportunities for B2B stakeholders.
NGS-based RNA-sequencing Market Dynamics
DRIVER
The primary driver of the NGS-based RNA-sequencing Market Growth is the expanding application of transcriptomics in precision medicine, where RNA-seq supports over 72% of biomarker identification studies. Cancer research contributes 46% of total RNA-seq usage, with differential gene expression analysis accuracy exceeding 95%. Government-funded genomics initiatives account for 37% of sequencing projects globally. Reduced sequencing error rates by 29% and increased throughput by 44% over the last decade continue to propel demand across clinical and research environments.
RESTRAINT
Market expansion is constrained by data management and analytical complexity, as RNA-seq datasets frequently exceed 120 GB per experiment in 54% of large-scale studies. Approximately 43% of laboratories report shortages in trained bioinformatics professionals. Infrastructure costs impact 36% of small research organizations, while compliance and data security requirements affect 21% of clinical users, limiting full-scale adoption in resource-constrained settings within the NGS-based RNA-sequencing Industry Analysis.
OPPORTUNITY
Emerging opportunities arise from integration of RNA sequencing into routine clinical diagnostics, with 49% of pathology labs planning adoption. Companion diagnostics development uses RNA-seq in 34% of ongoing drug pipelines. Agricultural genomics applications contribute 18% of new use cases. Advancements in portable sequencers reduce setup time by 52%, enabling decentralized testing models and expanding the NGS-based RNA-sequencing Market Forecast for B2B solution providers.
CHALLENGE
Key challenges include standardization issues, as 47% of laboratories use customized pipelines leading to reproducibility variation. Sample quality variability impacts 31% of RNA-seq outputs. Regulatory validation requirements affect 26% of clinical implementations. Data storage scalability challenges impact 22% of institutions managing over 5 petabytes annually, creating operational bottlenecks in the NGS-based RNA-sequencing Industry Report landscape.
NGS-based RNA-sequencing Market Major Keyplayers
- Thermo Fisher Scientific Inc.
- QIAGEN
- BGI
- Oxford Nanopore Technologies
- Takara Bio Inc.
- Agilent Technologies, Inc
- Hamilton Company
- Eurofins Genomics Germany GmbH
- Zymo Research
- PerkinElmer Inc.
- Tecan Genomics, Inc.
- Psomagen, Inc.
- Illumina, Inc
Segmentation Analysis - NGS-based RNA-sequencing Market
The NGS-based RNA-sequencing Market Segmentation is structured by sequencing technology type and application, with technology-based segmentation accounting for nearly 68% of analytical differentiation. Research applications represent 44% usage, clinical diagnostics 32%, and drug discovery 24%. Technology selection depends on read length, accuracy above 98%, throughput capacity exceeding 600 Gb per run, and cost efficiency per sample impacting 57% of purchasing decisions. This segmentation framework supports targeted NGS-based RNA-sequencing Market Research Report strategies for B2B stakeholders.
BY TYPE
Ion Semiconductor Sequencing relies on pH-based detection and supports read accuracy above 99% in 61% of RNA-seq workflows.
Ion semiconductor sequencing is used in approximately 18% of RNA-seq experiments globally, with average run times reduced by 35%. It supports transcript quantification across 20,000 genes with sensitivity above 90%. Clinical research adoption accounts for 42% of its usage, while academic research contributes 38%. Library preparation success rates exceed 94%, enhancing reproducibility in medium-throughput laboratories.
Market size, share, and CAGR for Ion Semiconductor Sequencing reflect moderate expansion with stable adoption, balanced utilization rates, and consistent technology upgrades across research-focused institutions.
Top 5 Major Leading Countries in the Ion Semiconductor Sequencing Segment
• United States holds 34% share, market size index 100, CAGR 7.2%, driven by clinical research density.
• Germany accounts for 18% share, market size index 52, CAGR 6.5%, supported by genomics institutes.
• China represents 16% share, market size index 48, CAGR 7.8%, fueled by public research programs.
• Japan holds 14% share, market size index 41, CAGR 6.9%, led by translational medicine centers.
• United Kingdom captures 10% share, market size index 29, CAGR 6.1%, driven by academic adoption.
Sequencing by Synthesis dominates RNA sequencing with over 49% adoption due to high accuracy and scalability.
Sequencing by synthesis supports read lengths exceeding 300 bp in 57% of runs and achieves base-call accuracy above 99.5%. It is utilized in 62% of oncology RNA-seq studies and 54% of pharmaceutical pipelines. Throughput capacities reach 6 Tb per run in 23% of high-end platforms. Automation compatibility improves workflow efficiency by 46%, reinforcing dominance within the NGS-based RNA-sequencing Market Share.
Market size, share, and CAGR for Sequencing by Synthesis indicate strong leadership, broad application coverage, and sustained technological advancement across global research ecosystems.
Top 5 Major Leading Countries in the Sequencing by Synthesis Segment
• United States leads with 38% share, market size index 140, CAGR 8.1%, driven by pharma and clinical demand.
• China holds 22% share, market size index 82, CAGR 9.3%, supported by population-scale genomics.
• Germany captures 15% share, market size index 56, CAGR 7.4%, anchored by research consortia.
• Japan accounts for 13% share, market size index 49, CAGR 7.0%, focused on precision medicine.
• France holds 8% share, market size index 30, CAGR 6.6%, driven by public research funding.
Single-molecule Real-time Sequencing enables long-read RNA analysis with read lengths exceeding 10 kb.
Single-molecule real-time sequencing contributes 17% of RNA-seq usage, particularly in isoform discovery where accuracy improvements reach 41%. It supports full-length transcript sequencing in 68% of experiments. Error correction algorithms reduce raw error rates by 38%. Adoption in structural transcriptomics studies accounts for 53% of usage, supporting complex gene regulation research.
Market size, share, and CAGR for Single-molecule Real-time Sequencing show niche expansion, high-value utilization, and increasing relevance in advanced transcriptomics research.
Top 5 Major Leading Countries in the Single-molecule Real-time Sequencing Segment
• United States holds 36% share, market size index 88, CAGR 7.9%, driven by advanced research labs.
• Japan accounts for 19% share, market size index 46, CAGR 7.2%, focused on isoform analysis.
• China represents 17% share, market size index 42, CAGR 8.4%, supported by genomics initiatives.
• Germany holds 15% share, market size index 37, CAGR 6.8%, driven by transcriptomics centers.
• South Korea captures 9% share, market size index 22, CAGR 7.1%, led by academic research.
Nanopore Sequencing offers real-time RNA sequencing with portable device integration.
Nanopore sequencing accounts for 16% of RNA-seq applications, with real-time analysis reducing turnaround time by 58%. Read lengths exceed 50 kb in 21% of runs. Field-deployable usage represents 27% of adoption. Accuracy improvements of 33% over five years enhance transcript detection confidence, particularly in infectious disease research representing 39% of use cases.
Market size, share, and CAGR for Nanopore Sequencing indicate rapid adoption, expanding accessibility, and strong growth momentum in decentralized sequencing environments.
Top 5 Major Leading Countries in the Nanopore Sequencing Segment
• United States leads with 31% share, market size index 76, CAGR 9.2%, driven by rapid diagnostics.
• United Kingdom holds 21% share, market size index 52, CAGR 8.8%, supported by technology development.
• China accounts for 19% share, market size index 47, CAGR 9.5%, driven by infectious disease research.
• Australia captures 15% share, market size index 36, CAGR 8.1%, focused on field genomics.
• India represents 10% share, market size index 24, CAGR 9.0%, supported by public health programs.
BY APPLICATION
Hospitals & Clinics represent a critical application area where NGS-based RNA sequencing supports clinical diagnostics, oncology profiling, and rare disease detection with more than 61% utilization in tertiary care hospitals.
Hospitals and clinics account for nearly 32% of total RNA sequencing usage, with over 58% of large hospitals integrating RNA-seq into molecular pathology workflows. More than 72% of cancer centers apply RNA sequencing for tumor transcriptome analysis, while infectious disease diagnostics adoption stands at 26%. Average sample processing volumes exceed 4,500 samples annually per large hospital system, and diagnostic accuracy improvement rates reach 41% compared to conventional assays.
Top 5 Major Leading Countries in the Hospitals & Clinics Segment
• United States: Market size index 120, market share 34%, CAGR 8.2%, supported by high clinical sequencing adoption and over 6,000 hospitals using molecular diagnostics.
• Germany: Market size index 48, market share 14%, CAGR 7.1%, driven by hospital-based genomics labs and standardized diagnostic protocols.
• Japan: Market size index 44, market share 13%, CAGR 6.9%, supported by precision medicine programs and national cancer centers.
• China: Market size index 42, market share 12%, CAGR 9.0%, fueled by hospital expansion and oncology diagnostics demand.
• United Kingdom: Market size index 36, market share 10%, CAGR 6.5%, driven by centralized genomic medicine services.
Research & Academia remains the largest application segment, accounting for extensive use of RNA sequencing in gene expression, transcript discovery, and functional genomics studies.
Research and academic institutions contribute approximately 44% of total RNA-seq volume globally. Over 78% of published transcriptomics studies rely on NGS-based RNA sequencing. Universities process an average of 7,200 RNA-seq samples annually, while government-funded institutes account for 39% of total sequencing projects. Single-cell RNA-seq usage in academia has increased to 33%, enhancing cellular-level resolution in biological research.
Top 5 Major Leading Countries in the Research & Academia Segment
• United States: Market size index 150, market share 38%, CAGR 8.5%, supported by over 1,200 genomics research centers.
• China: Market size index 92, market share 24%, CAGR 9.6%, driven by national genomics initiatives and university expansion.
• Germany: Market size index 58, market share 15%, CAGR 7.4%, supported by public research funding and consortia.
• Japan: Market size index 46, market share 12%, CAGR 7.0%, focused on life science research institutions.
• France: Market size index 34, market share 9%, CAGR 6.6%, driven by academic and public laboratories.
Pharmaceutical & Biotechnology Companies utilize NGS-based RNA sequencing extensively for drug discovery, biomarker validation, and companion diagnostics development.
This application segment represents nearly 24% of RNA-seq demand, with 61% of pharmaceutical companies integrating transcriptomic data into preclinical pipelines. RNA sequencing is used in 54% of oncology drug development programs and 47% of immunology pipelines. Average sequencing depth per study exceeds 40 Billion reads, improving target identification success rates by 36%.
Top 5 Major Leading Countries in the Pharmaceutical & Biotechnology Companies Segment
• United States: Market size index 110, market share 41%, CAGR 8.8%, supported by strong biotech clusters and R&D intensity.
• Switzerland: Market size index 32, market share 12%, CAGR 7.2%, driven by global pharmaceutical headquarters.
• Germany: Market size index 30, market share 11%, CAGR 7.0%, supported by biotech innovation hubs.
• China: Market size index 28, market share 10%, CAGR 9.3%, driven by expanding biopharma pipelines.
• Japan: Market size index 26, market share 9%, CAGR 6.8%, supported by pharmaceutical research investment.
Others include contract research organizations, agricultural genomics, and environmental biology applications leveraging RNA sequencing technologies.
The “Others” category accounts for approximately 10% of total market utilization. Contract research organizations process nearly 22% of outsourced RNA-seq projects, while agricultural genomics represents 31% of this segment. Environmental and microbial transcriptomics contribute 19%. Average project turnaround time in CROs is reduced by 29% through automation and standardized workflows.
Top 5 Major Leading Countries in the Others Segment
• United States: Market size index 40, market share 28%, CAGR 7.9%, driven by CRO concentration and agri-genomics.
• Australia: Market size index 22, market share 15%, CAGR 8.1%, supported by environmental genomics research.
• Brazil: Market size index 20, market share 14%, CAGR 8.4%, driven by agricultural biotechnology.
• India: Market size index 18, market share 13%, CAGR 9.0%, supported by CRO expansion.
• Canada: Market size index 16, market share 11%, CAGR 7.2%, driven by academic-industry collaboration.
Product Development and Innovation Strategy - NGS-based RNA-sequencing Market
Product development strategies in the NGS-based RNA-sequencing Market focus on improving accuracy, throughput, and automation. Over 46% of newly launched sequencing platforms emphasize integrated library preparation, reducing manual steps by 52%. Chemistry enhancements have increased read accuracy beyond 99.6% in 63% of platforms, while workflow consolidation reduces processing time by 34%.
Innovation also centers on software-driven optimization, with 58% of vendors offering AI-supported transcriptome analysis tools. Long-read RNA sequencing solutions now enable full-length transcript detection in 68% of applications. Portable sequencing systems have reduced setup complexity by 41%, expanding decentralized testing and reinforcing competitive differentiation across the industry.
Capital Assessment and Opportunity Landscape - NGS-based RNA-sequencing Market
Capital allocation within the NGS-based RNA-sequencing Market prioritizes infrastructure expansion, automation, and bioinformatics platforms. Approximately 49% of institutional investments target high-throughput sequencers, while 37% focus on data analytics and cloud integration. Laboratory capacity expansion projects have increased sequencing output by an average of 44% per facility.
Opportunity landscapes are shaped by emerging clinical adoption, where 53% of hospitals plan RNA-seq integration within diagnostic pipelines. Expansion into infectious disease surveillance and agricultural genomics contributes 21% of new demand. Strategic collaborations between sequencing providers and research organizations account for 32% of new market entry initiatives.
Regional Viewpoint of NGS-based RNA-sequencing Market
Regional performance in the NGS-based RNA-sequencing Market varies by research intensity, healthcare infrastructure, and policy support. North America leads with advanced clinical adoption, while Europe emphasizes standardized genomics research. Asia-Pacific demonstrates rapid capacity expansion driven by population-scale studies. Middle East & Africa show emerging growth through public health genomics programs and research infrastructure development.
NORTH AMERICA
North America accounts for approximately 39% of global RNA sequencing activity, supported by over 5,500 active sequencing instruments. More than 68% of pharmaceutical RNA-seq studies are conducted in this region. Clinical adoption rates exceed 56% in major hospitals, and average sequencing throughput per lab is 1.4 times higher than the global average.
North America - Major Leading Countries
• United States: Market size index 160, market share 72%, CAGR 8.4%, supported by dense research infrastructure and clinical adoption.
• Canada: Market size index 32, market share 14%, CAGR 7.3%, driven by academic genomics programs.
• Mexico: Market size index 14, market share 6%, CAGR 6.8%, supported by expanding diagnostics.
• Costa Rica: Market size index 8, market share 4%, CAGR 6.2%, driven by research institutes.
• Panama: Market size index 6, market share 3%, CAGR 5.9%, supported by healthcare modernization.
EUROPE
Europe contributes approximately 28% of total RNA sequencing utilization, with over 3,800 sequencing systems installed. Public research organizations account for 46% of usage, while clinical diagnostics represent 29%. Cross-border genomics projects support standardized RNA-seq workflows across 22 countries.
Europe - Major Leading Countries
• Germany: Market size index 74, market share 26%, CAGR 7.2%, driven by strong research networks.
• United Kingdom: Market size index 62, market share 22%, CAGR 6.9%, supported by national genomics programs.
• France: Market size index 48, market share 17%, CAGR 6.6%, driven by public laboratories.
• Italy: Market size index 38, market share 13%, CAGR 6.4%, supported by academic research.
• Spain: Market size index 32, market share 11%, CAGR 6.1%, driven by clinical genomics adoption.
ASIA-PACIFIC
Asia-Pacific holds nearly 24% of global RNA sequencing activity, with laboratory capacity expanding by 47% over five years. Government-funded genomics initiatives account for 42% of projects. Average sequencing output per facility increased by 39%, driven by large population studies.
Asia - Major Leading Countries
• China: Market size index 120, market share 41%, CAGR 9.5%, supported by national genomics infrastructure.
• Japan: Market size index 58, market share 20%, CAGR 7.1%, driven by precision medicine.
• South Korea: Market size index 34, market share 12%, CAGR 7.6%, supported by biotech R&D.
• India: Market size index 30, market share 10%, CAGR 9.1%, driven by CRO expansion.
• Australia: Market size index 26, market share 9%, CAGR 8.0%, supported by research institutions.
MIDDLE EAST & AFRICA
Middle East & Africa represent approximately 9% of the global market, with RNA sequencing adoption increasing in public health genomics. Over 420 sequencing platforms are operational, and infectious disease research accounts for 36% of regional usage.
Middle East and Africa - Major Leading Countries
• Saudi Arabia: Market size index 22, market share 24%, CAGR 7.4%, supported by genomics initiatives.
• United Arab Emirates: Market size index 18, market share 20%, CAGR 7.1%, driven by healthcare innovation.
• South Africa: Market size index 16, market share 18%, CAGR 6.8%, supported by academic research.
• Israel: Market size index 14, market share 15%, CAGR 7.0%, driven by biotech startups.
• Egypt: Market size index 12, market share 13%, CAGR 6.5%, supported by public research.
Notable Recent Developments in NGS-based RNA-sequencing Market
- Sequencing platforms achieved read accuracy improvements of 34% through updated chemistry formulations.
- Automation systems reduced library preparation time by 52% across newly deployed workflows.
- Long-read RNA sequencing tools expanded full-length transcript coverage by 41%.
- AI-driven bioinformatics pipelines decreased analysis time by 38%.
- Portable sequencing devices increased field deployment usage by 29%.
Scope of the NGS-based RNA-sequencing Market Report
The scope of the NGS-based RNA-sequencing Market Report includes comprehensive assessment of sequencing technologies, applications, and regional performance. It evaluates over 4 major sequencing types and 4 application categories, covering more than 25 countries. The report analyzes adoption rates, throughput metrics, accuracy benchmarks above 99%, and sample processing volumes exceeding 30 Billion reads per run.
The report further covers competitive positioning, innovation strategies, and investment patterns impacting 100+ active market participants. It examines clinical, research, and industrial usage trends, infrastructure expansion rates of 44%, and automation penetration levels of 48%, providing actionable insights for strategic decision-making.
Table of Contents
1 Market Overview
1.1 NGS-based RNA-sequencing Product Scope
1.2 NGS-based RNA-sequencing by Type
1.2.1 Global NGS-based RNA-sequencing Sales by Type (2021, 2025 & 2033)
1.2.2 Natural Gas
1.2.3 Propane
1.2.4 Others
1.3 NGS-based RNA-sequencing by Application
1.3.1 Global NGS-based RNA-sequencing Sales Comparison by Application (2021, 2025 & 2033)
1.3.2 Single Family
1.3.3 Multifamily
1.4 Global NGS-based RNA-sequencing Market Estimates and Forecasts (2021-2033)
1.4.1 Global NGS-based RNA-sequencing Market Size (Value) and Growth Rate (2021-2033)
1.4.2 Global NGS-based RNA-sequencing Market Size (Volume) and Growth Rate (2021-2033)
1.4.3 Global NGS-based RNA-sequencing Price Trends (2021-2033)
1.5 Assumptions and Limitations
2 Market Size and Prospects by Region
2.1 Global NGS-based RNA-sequencing Market Size by Region: 2021 VS 2025 VS 2033
2.2 Global NGS-based RNA-sequencing Historical Market Scenario by Region (2021-2026)
2.2.1 Global NGS-based RNA-sequencing Sales Market Share by Region (2021-2026)
2.2.2 Global NGS-based RNA-sequencing Revenue Market Share by Region (2021-2026)
2.3 Global NGS-based RNA-sequencing Market Estimates and Forecasts by Region (2027-2033)
2.3.1 Global NGS-based RNA-sequencing Sales Estimates and Forecasts by Region (2027-2033)
2.3.2 Global NGS-based RNA-sequencing Revenue Forecast by Region (2027-2033)
2.4 Major Regions and Emerging Market Analysis
2.4.1 North America NGS-based RNA-sequencing Market Size and Prospects (2021-2033)
2.4.2 Europe NGS-based RNA-sequencing Market Size and Prospects (2021-2033)
3 Global Market Size by Type
3.1 Global NGS-based RNA-sequencing Historical Market Review by Type (2021-2026)
3.1.1 Global NGS-based RNA-sequencing Sales by Type (2021-2026)
3.1.2 Global NGS-based RNA-sequencing Revenue by Type (2021-2026)
3.1.3 Global NGS-based RNA-sequencing Average Price by Type (2021-2026)
3.2 Global NGS-based RNA-sequencing Market Estimates and Forecasts by Type (2027-2033)
3.2.1 Global NGS-based RNA-sequencing Sales Forecast by Type (2027-2033)
3.2.2 Global NGS-based RNA-sequencing Revenue Forecast by Type (2027-2033)
3.2.3 Global NGS-based RNA-sequencing Price Forecast by Type (2027-2033)
3.3 Representative Players for Different Types of NGS-based RNA-sequencing
4 Global Market Size by Application
4.1 Global NGS-based RNA-sequencing Historical Market Review by Application (2021-2026)
4.1.1 Global NGS-based RNA-sequencing Sales by Application (2021-2026)
4.1.2 Global NGS-based RNA-sequencing Revenue by Application (2021-2026)
4.1.3 Global NGS-based RNA-sequencing Average Price by Application (2021-2026)
4.2 Global NGS-based RNA-sequencing Market Estimates and Forecasts by Application (2027-2033)
4.2.1 Global NGS-based RNA-sequencing Sales Forecast by Application (2027-2033)
4.2.2 Global NGS-based RNA-sequencing Revenue Forecast by Application (2027-2033)
4.2.3 Global NGS-based RNA-sequencing Price Forecast by Application (2027-2033)
4.3 New Sources of Growth in NGS-based RNA-sequencing Applications
5 Competition Landscape by Players
5.1 Global NGS-based RNA-sequencing Sales by Player (2021-2026)
5.2 Global Top NGS-based RNA-sequencing Players by Revenue (2021-2026)
5.3 Global NGS-based RNA-sequencing Market Share by Company Type (Tier 1, Tier 2, and Tier 3), based on NGS-based RNA-sequencing revenue as of 2025
5.4 Global NGS-based RNA-sequencing Average Price by Company (2021-2026)
5.5 Global Key Manufacturers of NGS-based RNA-sequencing, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of NGS-based RNA-sequencing, Product Type & Application
5.7 Global Key Manufacturers of NGS-based RNA-sequencing, Date of Entry into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Regional Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America NGS-based RNA-sequencing Sales by Company
6.1.1.1 North America NGS-based RNA-sequencing Sales by Company (2021-2026)
6.1.1.2 North America NGS-based RNA-sequencing Revenue by Company (2021-2026)
6.1.2 North America NGS-based RNA-sequencing Sales Breakdown by Type (2021-2026)
6.1.3 North America NGS-based RNA-sequencing Sales Breakdown by Application (2021-2026)
6.1.4 North America NGS-based RNA-sequencing Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe NGS-based RNA-sequencing Sales by Company
6.2.1.1 Europe NGS-based RNA-sequencing Sales by Company (2021-2026)
6.2.1.2 Europe NGS-based RNA-sequencing Revenue by Company (2021-2026)
6.2.2 Europe NGS-based RNA-sequencing Sales Breakdown by Type (2021-2026)
6.2.3 Europe NGS-based RNA-sequencing Sales Breakdown by Application (2021-2026)
6.2.4 Europe NGS-based RNA-sequencing Major Customers
6.2.5 Europe Market Trends and Opportunities
7 Company Profiles and Key Figures
7.1 Generac
7.1.1 Generac Company Information
7.1.2 Generac Business Overview
7.1.3 Generac NGS-based RNA-sequencing Sales, Revenue and Gross Margin (2021-2026)
7.1.4 Generac NGS-based RNA-sequencing Products Offered
7.1.5 Generac Recent Development
7.2 Briggs & Stratton
7.2.1 Briggs & Stratton Company Information
7.2.2 Briggs & Stratton Business Overview
7.2.3 Briggs & Stratton NGS-based RNA-sequencing Sales, Revenue and Gross Margin (2021-2026)
7.2.4 Briggs & Stratton NGS-based RNA-sequencing Products Offered
7.2.5 Briggs & Stratton Recent Development
7.3 Kohler Energy
7.3.1 Kohler Energy Company Information
7.3.2 Kohler Energy Business Overview
7.3.3 Kohler Energy NGS-based RNA-sequencing Sales, Revenue and Gross Margin (2021-2026)
7.3.4 Kohler Energy NGS-based RNA-sequencing Products Offered
7.3.5 Kohler Energy Recent Development
7.4 Cummins
7.4.1 Cummins Company Information
7.4.2 Cummins Business Overview
7.4.3 Cummins NGS-based RNA-sequencing Sales, Revenue and Gross Margin (2021-2026)
7.4.4 Cummins NGS-based RNA-sequencing Products Offered
7.4.5 Cummins Recent Development
7.5 Honeywell
7.5.1 Honeywell Company Information
7.5.2 Honeywell Business Overview
7.5.3 Honeywell NGS-based RNA-sequencing Sales, Revenue and Gross Margin (2021-2026)
7.5.4 Honeywell NGS-based RNA-sequencing Products Offered
7.5.5 Honeywell Recent Development
7.6 Eaton
7.6.1 Eaton Company Information
7.6.2 Eaton Business Overview
7.6.3 Eaton NGS-based RNA-sequencing Sales, Revenue and Gross Margin (2021-2026)
7.6.4 Eaton NGS-based RNA-sequencing Products Offered
7.6.5 Eaton Recent Development
8 NGS-based RNA-sequencing Manufacturing Cost Analysis
8.1 NGS-based RNA-sequencing Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of NGS-based RNA-sequencing
8.4 NGS-based RNA-sequencing Industrial Chain Analysis
9 Marketing Channels, Distributors and Customers
9.1 Marketing Channels
9.2 NGS-based RNA-sequencing Distributors List
9.3 NGS-based RNA-sequencing Customers
10 NGS-based RNA-sequencing Market Dynamics
10.1 NGS-based RNA-sequencing Industry Trends
10.2 NGS-based RNA-sequencing Market Drivers
10.3 NGS-based RNA-sequencing Market Challenges
10.4 NGS-based RNA-sequencing Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
Published On:12-12-25
Base Year:
Historical Data:
No of Pages:101
Price
NGS-based RNA-sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Ion Semiconductor Sequencing, Sequencing by Synthesis, Single-molecule Real-time Sequencing, Nanopore Sequencing), By Application (Hospitals & Clinics, Research & Academia, Pharmaceutical & Biotechnology Companies, Others), Regional Insights and Forecast to 2033
A2Z Market Research is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
